Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

Inclusion criteria

• Age range of 18-75 years old (including both ends), gender not limited;
• Patients with locally advanced unresectable or metastatic non-small cell lung cancer diagnosed by pathology
• ECOG score is 0 or 1
• Expected survival period ≥ 12 weeks
• Has a good level of organ function
• Patients voluntarily joined the study and signed informed consent

Exclusion criteria

• Having difficulty swallowing or malabsorption syndrome or any other uncontrolled gastrointestinal disease (such as nausea, diarrhea, or vomiting), having undergone gastrectomy or gastric banding surgery, etc
• Symptomatic or active central nervous system tumor metastasis
• Previously or simultaneously suffering from other malignant tumors
• Spinal cord compression that cannot be cured by surgery and/or radiotherapy
• Accompanied by uncontrolled tumor related pain
• Plan to receive any other anti-tumor treatment during this trial period
• Receive other anti-tumor treatments within 4 weeks before the first medication
• Having undergone major surgeries other than diagnosis or biopsy within 28 days prior to the first administration
• Currently participating in other clinical studies or taking medication for the first time less than 4 weeks after the end of the previous clinical study
• Moderate to severe pleural effusion with clinical symptoms
• Individuals with active pulmonary tuberculosis infection within one year prior to the first use of medication
• Subjects who have experienced severe infections within 30 days prior to their first medication use
• Administer attenuated live vaccine within 30 days before the first use of medication.
• History of immunodeficiency
• Suffering from poorly controlled or severe cardiovascular and cerebrovascular diseases
• History of interstitial pneumonia/non infectious pneumonia requiring hormone therapy in the past
• AE caused by previous anti-tumor treatment has not recovered to CTCAE v5.0 level evaluation ≤ 1
• Untreated active hepatitis
• Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.
• There are other serious physical or mental illnesses or laboratory abnormalities present